当前位置: 首页 > 详情页

A systematic review of pipeline embolization device for giant intracranial aneurysms

文献详情

资源类型:

收录情况: ◇ SCIE

机构: [1]Capital Med Univ, Beijing Neurosurg Inst, Beijing, Peoples R China; [2]Capital Med Univ, Beijing Tiantan Hosp, Beijing, Peoples R China; [3]Beijing Neurosurg Inst, 6 Dongcheng, Beijing 100050, Peoples R China; [4]Beijing Tiantan Hosp, 6 Dongcheng, Beijing 100050, Peoples R China
出处:
ISSN:

关键词: Aneurysms embolization device giant intracranial pipeline

摘要:
The experience with respect to the treatment of giant intracranial aneurysms with flow-diversion devices is limited. The aim of the present systematic review was to evaluate the effect of the pipeline embolization device (PED) on giant intracranial aneurysms. Eligible related articles were identified by searching the PubMed, Web of Science, Springer, ScienceDirect, and OVID databases using "giant aneurysm" and "pipeline" as the search items. The date of the last search was November 20, 2015. This systematic review adopted the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. In a total of 9 eligible studies with 200 patients and 215 aneurysms, 40 (18.6%) giant (aneurysm diameter >25mm) intracranial aneurysms treated with PED were analyzed. During a 6 to 34 month follow-up, complete occlusion was achieved in 23 (57.5%) cases. Seven patients (17.5%) developed intracranial hemorrhage, 5 developed ischemic attack (12.5%), and 13 (32.5%) developed a mass effect after PED treatment. The complication rate was 77.8% in PED for giant vertebrobasilar artery aneurysms. The cumulative mortality rate for giant paraclinoid carotid artery and middle cerebral artery aneurysms was 13.3% and increased up to 50% for giant vertebrobasilar artery aneurysms. The complete obliteration rate of PED for giant intracranial aneurysms was approximately 60%. Mass effect is the most mechanism of complications. Complication and mortality rates associated with PED for giant vertebrobasilar artery aneurysms are still extremely high.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2016]版:
大类 | 4 区 医学
小类 | 4 区 神经科学
最新[2023]版:
大类 | 3 区 医学
小类 | 4 区 神经科学
JCR分区:
出版当年[2015]版:
Q4 NEUROSCIENCES
最新[2023]版:
Q4 NEUROSCIENCES

影响因子: 最新[2023版] 最新五年平均 出版当年[2015版] 出版当年五年平均 出版前一年[2014版] 出版后一年[2016版]

第一作者:
第一作者机构: [1]Capital Med Univ, Beijing Neurosurg Inst, Beijing, Peoples R China; [2]Capital Med Univ, Beijing Tiantan Hosp, Beijing, Peoples R China; [3]Beijing Neurosurg Inst, 6 Dongcheng, Beijing 100050, Peoples R China; [4]Beijing Tiantan Hosp, 6 Dongcheng, Beijing 100050, Peoples R China
通讯作者:
通讯机构: [1]Capital Med Univ, Beijing Neurosurg Inst, Beijing, Peoples R China; [2]Capital Med Univ, Beijing Tiantan Hosp, Beijing, Peoples R China; [3]Beijing Neurosurg Inst, 6 Dongcheng, Beijing 100050, Peoples R China; [4]Beijing Tiantan Hosp, 6 Dongcheng, Beijing 100050, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16409 今日访问量:0 总访问量:869 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院